Innovation in Mitochondrial Health
What We Do
Our Value Propositions.
Click on each of our three value propositions below to find out more about our offering and how it may be of benefit to you.
Over 100 Mitochondrial Health Parameters
Comprehensive reports covering many aspects of mitochondrial health enable informed decisions to be made.
Improved Translation Confidence
The use of patient-derived cells are accurate disease relevant models, improving confidence in translation.
Valuable IND Application Evidence
Efficacy data in accurate human cell based models can provide valuable evidence for an IND application.
A Comprehensive Evaluation of Mitochondrial Health
Our state of the art techniques offer miniaturisation of complex biological assays in patient-derived cells enabling us to run high throughput screens to measure hundreds of mitochondrial health parameters.
We can measure function, morphology, localisation, mtDNA, mitochondria interactions with other organelles and mitochondrial ROS production in 1536 well plates in patient cells.
Further exploration of respiration, fuel consumption, mitophagy and many other aspects of mitochondrial biology can be investigated in in-depth screens in primary cells and induced cell types such as iNeurons and iAstrocytes.
We can also provide data on cell health, including cell viability, morphology and apoptotic markers.
This enables customers to confidently make well informed decisions about compound progression and stop compounds that would often be identified as ineffective at later stages of discovery. This will save time and money.
Why settle for less when you can have more for the same price?
Translation
Complex diseases such as neurodegeneration are incredibly hard to replicate in the lab. Patient-derived cells provide the closest representative model of these diseases.
The use of patient-derived cells enables the collection of data for IND applications and reduces the use of animal models, presenting a more ethical option.
Compound efficacy in patient-derived cell lines improves the confidence that the compound will be successful in patients.
At mitotype, we use patient-derived cells in early drug discovery enabling rapid termination of ineffective compounds saving companies money.
Our screening in patient-derived cells is as fast as other conventional generic cell models.
Patient-derived cells can also be reprogrammed to enable the production of cell types that cannot be biopsied.
Investigational New Drug Application
The FDA Modernization Act 2.0, passed in 2022, authorises the use of cell-based models instead of animal models to investigate drug safety and effectiveness
Our patient-derived cells provide strong models to collect data proving compound mechanisms and effectiveness for IND applications.
Our in-depth analysis would provide comprehensive reports for approval.
The use of cell models dramatically reduces the use of animals presenting a more ethical option.
Get in touch with our team!
If you would like any further information please get in touch via the form below or email tjburgess1@sheffield.ac.uk